Polymorphisms of MDR1, CYP2C19 and P2Y12 genes in Indian population: Effects on clopidogrel response

Yusuf, 2001, Effects of Clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation, N Engl J Med, 345, 494, 10.1056/NEJMoa010746 Sabatine, 2005, Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation, N Engl J Med, 352, 1179, 10.1056/NEJMoa050522 King, 2008, Circulation, 117, 261, 10.1161/CIRCULATIONAHA.107.188208 Gurbel, 2003, Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity, Circulation, 107, 2908, 10.1161/01.CIR.0000072771.11429.83 Muller, 2003, Prevalence of Clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement, Thromb Haemost, 89, 783, 10.1055/s-0037-1613462 Nguyen, 2005, Resistance to clopidogrel: a review of the evidence, J Am Coll Cardiol, 45, 1157, 10.1016/j.jacc.2005.01.034 Wiviott, 2004, Clopidogrel resistance: a new chapter in a fast-moving story, Circulation, 109, 3064, 10.1161/01.CIR.0000134701.40946.30 Taubert, 2006, Impact of P-glycoprotein on clopidogrel absorption, Clin Pharmacol Ther, 80, 486, 10.1016/j.clpt.2006.07.007 Fung, 2009, A synonymous polymorphism in a common MDR1 (ABCB1) haplotype shapes protein function, (BBA)—Proteins and Proteomics, 1794, 860, 10.1016/j.bbapap.2009.02.014 Tang, 2004, Genomic evidence for recent positive selection at the human MDR1 gene locus, Hum Mol Genet, 13, 783, 10.1093/hmg/ddh099 Kazui, 2010, Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite, Drug Metab Dispos, 38, 92, 10.1124/dmd.109.029132 De Morais, 1994, Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese, Mol Pharmacol, 46, 594 De Morais, 1994, The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans, J Biol Chem, 269, 15419, 10.1016/S0021-9258(17)40694-6 Hulot, 2006, Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects, Blood, 108, 2244, 10.1182/blood-2006-04-013052 Brandt, 2007, Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel, J Thromb Haemost, 5, 2429, 10.1111/j.1538-7836.2007.02775.x Trenk, 2008, Cytochrome P450 2C19 681G>A polymorphism and high on-Clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug eluting or bare-metal stents, J Am Coll Cardiol, 51, 1925, 10.1016/j.jacc.2007.12.056 Sim, 2006, A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants, Clin Pharmacol Ther, 79, 103, 10.1016/j.clpt.2005.10.002 Sibbing, 2010, Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement, Circulation, 121, 512, 10.1161/CIRCULATIONAHA.109.885194 Hollopeter, 2001, Identification of the platelet ADP receptor targeted by antithrombotic drugs, Nature, 409, 202, 10.1038/35051599 Fontana, 2003, Adenosine diphosphate – induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects, Circulation, 108, 989, 10.1161/01.CIR.0000085073.69189.88 Balram, 2003, Frequency of C3435T single nucleotide MDR1 genetic polymorphism in an Asian population: phenotypic–genotypic correlates, Br J Clin Pharmacol, 56, 78, 10.1046/j.1365-2125.2003.01820.x Ashavaid, 2010, Effect of gene polymorphisms on the levels of calcineurin inhibitors in Indian renal transplant recipients, Indian J Nephrol, 20, 146, 10.4103/0971-4065.70846 Adithan, 2003, Allele and genotype frequency of CYP2C19 in a Tamilian population, Br J Clin Pharmacol, 56, 331, 10.1046/j.1365-2125.2003.01883.x Panchabhai, 2006, Evaluation of the activity of CYP2C19 in Gujrati and Marwadi subjects living in Mumbai (Bombay), BMC Clin Pharmacol, 24, 6 Ellis, 2009, Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendations, Pharmacogenomics, 10, 1799, 10.2217/pgs.09.143 Siller-Matula, 2009, Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel, Am Heart J, 157, 148e1, 10.1016/j.ahj.2008.09.017 Cattaneo, 2004, Aspirin and clopidogrel: efficacy, safety and the issue of drug resistance, Arterioscler Thromb Vasc Biol, 24, 1980, 10.1161/01.ATV.0000145980.39477.a9 Dörr, 2002, Effects of combined therapy with clopidogrel and acetylsalicylic acid on platelet glycoprotein expression and aggregation, J Cardiovasc Pharmacol, 39, 523, 10.1097/00005344-200204000-00008 Wilkinson, 2005, Drug metabolism and variability among patients in drug response, N Engl J Med, 352, 2211, 10.1056/NEJMra032424 Miller, 1988, A simple salting out procedure for extracting DNA from human nucleated cells, Nucleic Acids Res, 16, 1215, 10.1093/nar/16.3.1215 Cizmarikova, 2010, MDR1 (C3435T) polymorphism: relation to the risk of breast cancer and therapeutic outcome, Pharmacogenomic J, 10, 62, 10.1038/tpj.2009.41 Malek, 2008, Coexisting polymorphisms of P2Y12 and CYP2C19 genes as a risk factor for persistent platelet activation with clopidogrel, Circ J, 72, 1165, 10.1253/circj.72.1165 Pang, 2004, Genetic polymorphism of Cytochrome P450 2C19 in healthy Malaysian subjects, Br J Clin Pharmacol, 58, 332, 10.1111/j.1365-2125.2004.02144.x Baldwin, 2008, Increased omeprazole metabolism in carriers of the CYP2C19*17 allele; a pharmacokinetic study in healthy volunteers, Br J Clin Pharmacol, 65, 767, 10.1111/j.1365-2125.2008.03104.x Xie, 2001, Molecular basis of ethnic differences in drug disposition and response, Annu Rev Pharmacol Toxicol, 41, 815, 10.1146/annurev.pharmtox.41.1.815 Mizutani, 2003, PM frequencies of major CYPs in Asians and Caucasians, Drug Metabol Rev, 35, 99, 10.1081/DMR-120023681 Giusti, 2007, Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients, Pharmacogenet Genomics, 17, 1057, 10.1097/FPC.0b013e3282f1b2be